CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors

Leonidas C. Platanias, Shahab Uddin, Edward Bruno, Mete Korkmaz, Sarfraz Ahmad, Yazan Alsayed, David Van Den Berg, Brian Druker, Amittha Wickrema, Ronald Hoffman

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Interferons are potent regulators of normal and malignant hematopoietic cell proliferation in vitro and in vivo, but the signaling mechanisms by which they exhibit their growth inhibitory effects are unknown. We have recently shown that CrkL is engaged in Type I IFN signaling, as shown by its rapid tyrosine phosphorylation during engagement of the Type I IFN receptor. In the present study, we provide evidence that the related CrkII protein is also rapidly phosphorylated on tyrosine during treatment of U-266 and Daudi cells with IFNα or IFNβ. We also show that both members of the Crk-family, CrkL and CrkII, are phosphorylated in an interferon-dependent manner in primary hematopoietic progenitors. Furthermore, inhibition of CrkL or CrkII protein expression by antisense oligonucleotides, reverses the inhibitory effects of IFNα or IFNγ on the proliferation of normal bone marrow progenitor cells (colony forming units-granulocytic/monocytic [CFU-GM] and burst-forming units-erythroid [BFU-E]). Thus, both CrkL and CrkII are engaged in a signaling pathway (s) that mediates interferon-regulated inhibition of hematopoietic cell proliferation.

Original languageEnglish (US)
Pages (from-to)1315-1321
Number of pages7
JournalExperimental Hematology
Volume27
Issue number8
DOIs
StatePublished - Aug 1999

Fingerprint

Interferons
Tyrosine
Stem Cells
Growth
Cell Proliferation
Erythroid Precursor Cells
Antisense Oligonucleotides
Bone Marrow Cells
Proteins
Phosphorylation
Inhibition (Psychology)
In Vitro Techniques

Keywords

  • Hematopoiesis
  • Interferons
  • Signal transduction

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. / Platanias, Leonidas C.; Uddin, Shahab; Bruno, Edward; Korkmaz, Mete; Ahmad, Sarfraz; Alsayed, Yazan; Van Den Berg, David; Druker, Brian; Wickrema, Amittha; Hoffman, Ronald.

In: Experimental Hematology, Vol. 27, No. 8, 08.1999, p. 1315-1321.

Research output: Contribution to journalArticle

Platanias, LC, Uddin, S, Bruno, E, Korkmaz, M, Ahmad, S, Alsayed, Y, Van Den Berg, D, Druker, B, Wickrema, A & Hoffman, R 1999, 'CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors', Experimental Hematology, vol. 27, no. 8, pp. 1315-1321. https://doi.org/10.1016/S0301-472X(99)00060-0
Platanias, Leonidas C. ; Uddin, Shahab ; Bruno, Edward ; Korkmaz, Mete ; Ahmad, Sarfraz ; Alsayed, Yazan ; Van Den Berg, David ; Druker, Brian ; Wickrema, Amittha ; Hoffman, Ronald. / CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. In: Experimental Hematology. 1999 ; Vol. 27, No. 8. pp. 1315-1321.
@article{0d1c3ef0a27c49c58f6662d296789a7b,
title = "CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors",
abstract = "Interferons are potent regulators of normal and malignant hematopoietic cell proliferation in vitro and in vivo, but the signaling mechanisms by which they exhibit their growth inhibitory effects are unknown. We have recently shown that CrkL is engaged in Type I IFN signaling, as shown by its rapid tyrosine phosphorylation during engagement of the Type I IFN receptor. In the present study, we provide evidence that the related CrkII protein is also rapidly phosphorylated on tyrosine during treatment of U-266 and Daudi cells with IFNα or IFNβ. We also show that both members of the Crk-family, CrkL and CrkII, are phosphorylated in an interferon-dependent manner in primary hematopoietic progenitors. Furthermore, inhibition of CrkL or CrkII protein expression by antisense oligonucleotides, reverses the inhibitory effects of IFNα or IFNγ on the proliferation of normal bone marrow progenitor cells (colony forming units-granulocytic/monocytic [CFU-GM] and burst-forming units-erythroid [BFU-E]). Thus, both CrkL and CrkII are engaged in a signaling pathway (s) that mediates interferon-regulated inhibition of hematopoietic cell proliferation.",
keywords = "Hematopoiesis, Interferons, Signal transduction",
author = "Platanias, {Leonidas C.} and Shahab Uddin and Edward Bruno and Mete Korkmaz and Sarfraz Ahmad and Yazan Alsayed and {Van Den Berg}, David and Brian Druker and Amittha Wickrema and Ronald Hoffman",
year = "1999",
month = "8",
doi = "10.1016/S0301-472X(99)00060-0",
language = "English (US)",
volume = "27",
pages = "1315--1321",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors

AU - Platanias, Leonidas C.

AU - Uddin, Shahab

AU - Bruno, Edward

AU - Korkmaz, Mete

AU - Ahmad, Sarfraz

AU - Alsayed, Yazan

AU - Van Den Berg, David

AU - Druker, Brian

AU - Wickrema, Amittha

AU - Hoffman, Ronald

PY - 1999/8

Y1 - 1999/8

N2 - Interferons are potent regulators of normal and malignant hematopoietic cell proliferation in vitro and in vivo, but the signaling mechanisms by which they exhibit their growth inhibitory effects are unknown. We have recently shown that CrkL is engaged in Type I IFN signaling, as shown by its rapid tyrosine phosphorylation during engagement of the Type I IFN receptor. In the present study, we provide evidence that the related CrkII protein is also rapidly phosphorylated on tyrosine during treatment of U-266 and Daudi cells with IFNα or IFNβ. We also show that both members of the Crk-family, CrkL and CrkII, are phosphorylated in an interferon-dependent manner in primary hematopoietic progenitors. Furthermore, inhibition of CrkL or CrkII protein expression by antisense oligonucleotides, reverses the inhibitory effects of IFNα or IFNγ on the proliferation of normal bone marrow progenitor cells (colony forming units-granulocytic/monocytic [CFU-GM] and burst-forming units-erythroid [BFU-E]). Thus, both CrkL and CrkII are engaged in a signaling pathway (s) that mediates interferon-regulated inhibition of hematopoietic cell proliferation.

AB - Interferons are potent regulators of normal and malignant hematopoietic cell proliferation in vitro and in vivo, but the signaling mechanisms by which they exhibit their growth inhibitory effects are unknown. We have recently shown that CrkL is engaged in Type I IFN signaling, as shown by its rapid tyrosine phosphorylation during engagement of the Type I IFN receptor. In the present study, we provide evidence that the related CrkII protein is also rapidly phosphorylated on tyrosine during treatment of U-266 and Daudi cells with IFNα or IFNβ. We also show that both members of the Crk-family, CrkL and CrkII, are phosphorylated in an interferon-dependent manner in primary hematopoietic progenitors. Furthermore, inhibition of CrkL or CrkII protein expression by antisense oligonucleotides, reverses the inhibitory effects of IFNα or IFNγ on the proliferation of normal bone marrow progenitor cells (colony forming units-granulocytic/monocytic [CFU-GM] and burst-forming units-erythroid [BFU-E]). Thus, both CrkL and CrkII are engaged in a signaling pathway (s) that mediates interferon-regulated inhibition of hematopoietic cell proliferation.

KW - Hematopoiesis

KW - Interferons

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=0032806841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032806841&partnerID=8YFLogxK

U2 - 10.1016/S0301-472X(99)00060-0

DO - 10.1016/S0301-472X(99)00060-0

M3 - Article

C2 - 10428508

AN - SCOPUS:0032806841

VL - 27

SP - 1315

EP - 1321

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 8

ER -